Johnson & Johnson reported strong Q3 earnings with a 6% sales increase and raised its full-year guidance, yet its stock dropped nearly 6% after a weak MedTech segment performance and costs from recent acquisitions. Despite the selloff, key drug sales like Tremfya and new launches like Icotyde show promising growth, supporting a bullish outlook with a price target of $306.56. Investors should watch the MedTech segment and upcoming catalysts like the December Enterprise Business Review for future direction.
As of Oct 14, 2026 18:11 WIB, Johnson & Johnson shares on Pluang are trading at USD 249.81, showing a modest gain of 0.48% for the day. The stock's market capitalization stands at $599.12 billion, reflecting its significant presence in the health sector. Despite the recent stock drop mentioned in the news, Pluang data shows a balanced investor interest with 57% buy orders and 43% sell orders, highlighting ongoing confidence in the company.
Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing r...
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
Johnson & Johnson increased its 2026 sales forecast to $101.2 billion and raised adjusted EPS guidance to $11.10 after reporting a 6% operational sales growth in Q3. The growth was driven by strong performance in its Innovative Medicine division, esp...
